Stockreport

VistaGen Therapeutics Achieves Target Patient Enrollment in the ELEVATE Study of AV-101 as an Adjunctive Treatment for Major Depressive Disorder

VistaGen Therapeutics, Inc.  (VTGN) 
Last vistagen therapeutics, inc. earnings: 2/13 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.vistagen.com